Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C-K, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83.
Villani E, Rabbiolo G, Nucci P. Ocular allergy as a risk factor for dry eye in adults and children. Curr Opin Allergy Clin Immunol. 2018;18:398–403.
Leonardi A, Modugno RL, Salami E. Allergy and dry eye disease. Ocul Immunol Inflamm. 2021;29:1168–76.
Dominick LO, Justin TK, Jennifer H, Eric B, Milton MH. Prevalence of allergic conjunctivitis, ocular surface disease subtypes, and mixed disease. Invest Ophthalmol Vis Sci. 2014;55:2751.
Akasaki Y, Inomata T, Sung J, Nakamura M, Kitazawa K, Shih KC, et al. Prevalence of comorbidity between dry eye and allergic conjunctivitis: a systematic review and meta-analysis. J Clin Med. 2022;11:3643.
Chen L, Pi L, Fang J, Chen X, Ke N, Liu Q. High incidence of dry eye in young children with allergic conjunctivitis in Southwest China. Acta Ophthalmol. 2016;94:e727–30.
Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5.
Nye M, Rudner S, Bielory L. Emerging therapies in allergic conjunctivitis and dry eye syndrome. Expert Opin Pharmacother. 2013;14:1449–65.
Nguyen E, Yanes D, Imadojemu S, Kroshinsky D. Evaluation of cyclosporine for the treatment of DRESS syndrome. JAMA Dermatol. 2020;156:704–6.
Fauquert J-L. Diagnosing and managing allergic conjunctivitis in childhood: the allergist’s perspective. Pediatr Allergy Immunol. 2019;30:405–14.
Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, et al. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017;62:286–301.
Gao M, Zhao L, Liang R, Zhu Q, Zhao Q, Kong X. Evaluation of the efficacy and safety of topical 0.05% cyclosporine eye drops (II) in the treatment of dry eye associated with Primary Sjögren’s Syndrome. Ocul Immunol Inflamm. 2023;31:1662–1668.
Labib BA, Chigbu DI. Therapeutic targets in allergic conjunctivitis. Pharm (Basel). 2022;15:547.
Bao J, Tian L, Meng Y, Wu B, Wang J, He J, et al. Total IgE in tears accurately reflects the severity and predicts the prognosis of seasonal allergic conjunctivitis. Clin Transl Allergy. 2022;12:e12139.
Lin X, Huang J-F, Liu Z. Large scale, prospective, multicenter, clinical evaluation of point-of-care lymphotoxin alpha (LTA) test in dry eye disease. Investig Ophthalmol Vis Sci. 2020;61:116.
Suárez-Cortés T, Merino-Inda N, Benitez-Del-Castillo JM. Tear and ocular surface disease biomarkers: a diagnostic and clinical perspective for ocular allergies and dry eye disease. Exp Eye Res. 2022;221:109121.
Rhim JW, Eom Y, Yoon EG, Park SY, Choi Y, Song JS, et al. Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction. Jpn J Ophthalmol. 2022;66:254–63.
Asian Dry Eye Association China Chapter. Chinese expert consensus on dry eye: definition and classification (2020). Chin J Ophthalmol. 2020;56:418–22.
Nelson JD, Havener VR, Cameron JD. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch Ophthalmol. 1983;101:1869–72.
Patel D, Wairkar S. Recent advances in cyclosporine drug delivery: challenges and opportunities. Drug Deliv Transl Res. 2019;9:1067–81.
Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea. 2012;31:1386–93.
Leong E, Pang Z, Stadnyk AW, Lin TJ. Calcineurin Aα contributes to IgE-dependent mast-cell mediator secretion in allergic inflammation. J Innate Immun. 2022;14:320–34.
Kam KW, Chen LJ, Wat N, Young AL. Topical olopatadine in the treatment of allergic conjunctivitis: a systematic review and meta-analysis. Ocul Immunol Inflamm. 2017;25:663–77.
Vichyanond P, Kosrirukvongs P. Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis. Curr Allergy Asthma Rep. 2013;13:308–14.
Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006;32:272–6.
Wan KH-N, Chen LJ, Rong SS, Pang CP, Young AL. Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis. Ophthalmology. 2013;120:2197–203.
Leonardi A, Messmer EM, Labetoulle M, Amrane M, Garrigue J-S, Ismail D, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103:125–31.
Cui H, Liu F, Fang Y, Wang T, Yuan B, Ma C. Neuronal FcεRIα directly mediates ocular itch via IgE-immune complex in a mouse model of allergic conjunctivitis. J Neuroinflamm. 2022;19:55.
Ambroziak AM, Szaflik J, Szaflik JP, Ambroziak M, Witkiewicz J, Skopiński P. Immunomodulation on the ocular surface: a review. Cent Eur J Immunol. 2016;41:195–208.
Hashimoto T, Mishra SK, Olivry T, Yosipovitch G. Periostin, an emerging player in itch sensation. J Invest Dermatol. 2021;141:2338–43.
Izuhara K, Nunomura S, Nanri Y, Ono J, Takai M, Kawaguchi A. Periostin: an emerging biomarker for allergic diseases. Allergy. 2019;74:2116–28.
García-Posadas L, Hodges RR, Diebold Y, Dartt DA. Context-dependent regulation of conjunctival goblet cell function by allergic mediators. Sci Rep. 2018;8:12162.
Yoon K-C, Jeong I-Y, Park Y-G, Yang S-Y. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26:431–7.
Keller C, Hellsten Y, Steensberg A, Pedersen BK. Differential regulation of IL-6 and TNF-alpha via calcineurin in human skeletal muscle cells. Cytokine. 2006;36:141–7.
Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNF-alpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol. 2000;84:504–8.
Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci USA. 2005;102:6467–72.
Kang MJ, Kim HS, Kim MS, Kim EC. The Correlation between matrix metalloproteinase-9 point-of-care immunoassay, tear film osmolarity, and ocular surface parameters. J Ophthalmol. 2022;2022:6132016.
Chen H, Chen H, Liang L, Zhong Y, Liang Y, Yu Y, et al. Evaluation of tear protein markers in dry eye disease with different lymphotoxin-alpha expression levels. Am J Ophthalmol. 2020;217:198–211.
Davies K, Mirza K, Tarn J, Howard-Tripp N, Bowman SJ, Lendrem D, et al. Fatigue in primary Sjögren’s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatol Int. 2019;39:1867–73.
Ma J, Li C, Zhao Y, Shen Z, Hu B, Peng R, et al. Ophthalmic manifestations are associated with reduced tear lymphotoxin-α levels in chronic ocular graft-versus-host disease. BMC Ophthalmol. 2022;22:18.
Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay. Ophthalmology. 2016;123:2300–8.
Park JY, Kim BG, Kim JS, Hwang JH. Matrix metalloproteinase 9 point-of-care immunoassay result predicts response to topical cyclosporine treatment in dry eye disease. Transl Vis Sci Technol. 2018;7:31.
Kuprash DV, Boitchenko VE, Yarovinsky FO, Rice NR, Nordheim A, Rühlmann A, et al. Cyclosporin A blocks the expression of lymphotoxin alpha, but not lymphotoxin beta, in human peripheral blood mononuclear cells. Blood. 2002;100:1721–7.
CAS PubMed Google Scholar
Author: Misty Turner
Last Updated: 1700158803
Views: 2153
Rating: 4.6 / 5 (108 voted)
Reviews: 95% of readers found this page helpful
Name: Misty Turner
Birthday: 1932-11-03
Address: 425 Shaw Haven, Adrianland, WI 04921
Phone: +4863596514674197
Job: Event Planner
Hobby: Motorcycling, Origami, Aquarium Keeping, Robotics, Photography, Gardening, Surfing
Introduction: My name is Misty Turner, I am a risk-taking, Adventurous, variegated, valuable, artistic, accomplished, apt person who loves writing and wants to share my knowledge and understanding with you.